Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer

Ji Son(The University of Texas MD Anderson Cancer Center), David S. Hong(The University of Texas MD Anderson Cancer Center), Daniel D. Karp(The University of Texas MD Anderson Cancer Center), Ying Yuan(The University of Texas MD Anderson Cancer Center), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Sarina A. Piha‐Paul(The University of Texas MD Anderson Cancer Center), Jordi Rodón(The University of Texas MD Anderson Cancer Center), Vivek Subbiah(Sarah Cannon), Apostolia M. Tsimberidou(The University of Texas MD Anderson Cancer Center), Siqing Fu(The University of Texas MD Anderson Cancer Center), Pedro T. Ramírez(Houston Methodist), Timothy A. Yap(The University of Texas MD Anderson Cancer Center), Amadeo B. Biter(The University of Texas MD Anderson Cancer Center), Heather Lin(The University of Texas MD Anderson Cancer Center), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Shubham Pant(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Ecaterina E. Dumbrava(The University of Texas MD Anderson Cancer Center), Aung Naing(The University of Texas MD Anderson Cancer Center)
Journal of Immunotherapy and Precision Oncology
January 6, 2023
Cited by 1


Related Papers